H.C. Wainwright analyst Robert Burns raised the firm’s price target on Relay Therapeutics to $46 from $43 and keeps a Buy rating on the shares after pulling its discounted cash flow-based valuation forward.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
- Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight
